March 12, 2024Open Access

Supplementary Figure 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

Key points are not available for this paper at this time.

Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Keller et al. (Tue,) studied this question.

Alana L. Keller

Lauren T. Reiman

Olivia Perez de

Building similarity graph...

Analyzing shared references across papers